Literature DB >> 24318884

Design and evaluation of clinically relevant SOFA-HDV ribozymes targeting HIV RNA.

Robert J Scarborough1, Michel V Lévesque, Jean-Pierre Perreault, Anne Gatignol.   

Abstract

Nucleic acid therapies targeting HIV replication have the potential to be used in conjunction with or in place of the standard small-molecule therapies. Among the different classes of nucleic acid therapies, several ribozymes (Rzs, RNA enzymes) have been developed to target HIV RNA. The design of Rzs targeting HIV RNA is complicated by the sequence diversity of viral strains and the structural diversity of their target sites. Using the SOFA-HDV Rz as an example, this chapter describes methods that can be used to design Rzs for controlling HIV replication. We describe how to (1) identify highly conserved Rz target sites in HIV RNA; (2) generate a set of Rzs with the potential to be used as therapeutics; and (3) screen these Rzs for activity against HIV production.

Mesh:

Substances:

Year:  2014        PMID: 24318884     DOI: 10.1007/978-1-62703-730-3_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  7 in total

1.  Effective inhibition of HIV-1 production by short hairpin RNAs and small interfering RNAs targeting a highly conserved site in HIV-1 Gag RNA is optimized by evaluating alternative length formats.

Authors:  Robert J Scarborough; Kelsey L Adams; Aïcha Daher; Anne Gatignol
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

2.  Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.

Authors:  Robert J Scarborough; Kelsey L Adams; Olivier Del Corpo; Aïcha Daher; Anne Gatignol
Journal:  J Vis Exp       Date:  2016-09-05       Impact factor: 1.355

3.  The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication.

Authors:  Guerline Clerzius; Eileen Shaw; Aïcha Daher; Samantha Burugu; Jean-François Gélinas; Thornin Ear; Lucile Sinck; Jean-Pierre Routy; Andrew J Mouland; Rekha C Patel; Anne Gatignol
Journal:  Retrovirology       Date:  2013-09-11       Impact factor: 4.602

Review 4.  RNA Interference Therapies for an HIV-1 Functional Cure.

Authors:  Robert J Scarborough; Anne Gatignol
Journal:  Viruses       Date:  2017-12-27       Impact factor: 5.048

5.  A U1i RNA that Enhances HIV-1 RNA Splicing with an Elongated Recognition Domain Is an Optimal Candidate for Combination HIV-1 Gene Therapy.

Authors:  Olivier Del Corpo; Ryan P Goguen; Camille M G Malard; Aïcha Daher; Susan Colby-Germinario; Robert J Scarborough; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-18       Impact factor: 8.886

6.  A Conserved Target Site in HIV-1 Gag RNA is Accessible to Inhibition by Both an HDV Ribozyme and a Short Hairpin RNA.

Authors:  Robert J Scarborough; Michel V Lévesque; Etienne Boudrias-Dalle; Ian C Chute; Sylvanne M Daniels; Rodney J Ouellette; Jean-Pierre Perreault; Anne Gatignol
Journal:  Mol Ther Nucleic Acids       Date:  2014-07-29       Impact factor: 10.183

7.  An Adaptive Defect Weighted Sampling Algorithm to Design Pseudoknotted RNA Secondary Structures.

Authors:  Kasra Zandi; Gregory Butler; Nawwaf Kharma
Journal:  Front Genet       Date:  2016-07-22       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.